Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

ReCode Therapeutics
6001 Forest Park Rd.
Dallas, TX 75235
Phone: 408-585-1718
https://recodetx.com/

ReCode Therapeutics is a biopharmaceutical company developing precision medicines for genetic respiratory diseases with significant unmet medical need. ReCode's diverse pipeline includes lead programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. The Company's proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.

Key Contact
Name
David Lockhart
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
03/28/20 $80,000,000 Series A Colt Ventures
Hunt Technology Ventures
MPM Capital
OrbiMed Advisors
Osage University Partners
Vida Ventures
undisclosed
09/19/23 $50,000,000 Series B Amgen Ventures
AyurMaya
BLV
EcoR1 Capital
Leaps by Bayer
MPM Capital
OrbiMed Advisors
Osage University Partners
Pfizer Venture Investments
Sanofi Ventures
Solasta Ventures
Vida Ventures
undisclosed